Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR3 | P49682 | 15/20 | 0.51 |
| ▸ | CFTR | P13569 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | PREP | P48147 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19927605 | 1.00 | CXCR3 (0.51) | CXCR3CFTRCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL19927132 | 0.95 | CXCR3 (0.49) | CXCR3PREP | |
| SCHEMBL19927134 | 0.95 | CXCR3 (0.49) | CXCR3PREP | |
| SCHEMBL19927133 | 0.95 | CXCR3 (0.49) | CXCR3PREP | |
| SCHEMBL19927271 | 0.91 | CXCR3 (0.52) | CXCR3CFTRCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL21567076 | 0.91 | CXCR3 (0.52) | CXCR3CFTRCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL19927280 | 0.91 | CXCR3 (0.52) | CXCR3CFTRCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL30377766 | 0.91 | CXCR3 (0.52) | CXCR3CFTRCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL19931815 | 0.87 | CXCR3 (0.47) | CXCR3CFTRPREP | |
| SCHEMBL19931776 | 0.87 | CXCR3 (0.65) | CXCR3CYP1A2CYP3A4CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3507275-B1 | CXCR3 RECEPTOR AGONISTS | RECEPTOS LLC (US) | 2023-04-26 | — | — | EP | disclosed |
| US-11040954-B1 | CXCR3 receptor agonists | RECEPTOS LLC (US) | 2021-06-22 | — | — | US | disclosed |
| US-20190345133-A1 | CXCR3 RECEPTOR AGONISTS | RECEPTOS LLC | 2019-11-14 | — | — | US | disclosed |
| EP-3507275-A1 | CXCR3 RECEPTOR AGONISTS | Celgene International II Sarl (CH) | 2019-07-10 | — | — | EP | disclosed |
| WO-2018045246-A1 | CXCR3 RECEPTOR AGONISTS | CELGENE INTERNATIONAL II SARL (CH) | 2018-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11040954-B1 | CXCR3 receptor agonists | CXCR3, CXCR1, CCR7 | CXCR3 1/4885CFTR 102/4885CYP1A2 1702/4885 |
| US-20190345133-A1 | CXCR3 RECEPTOR AGONISTS | CXCR3, CXCR1, CCR7 | CXCR3 1/4885CFTR 102/4885CYP1A2 1702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.